Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3).
Authors
Sreenivasa R Chandana
Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI
Sreenivasa R Chandana , Zev A. Wainberg , Davide Melisi , Teresa Macarulla , Roberto A. Pazo Cid , Christelle De La Fouchardiere , Andrew Peter Dean , Igor Kiss , Woo Jin Lee , Thorsten Goetze , Eric Van Cutsem , Andrew Scott Paulson , Tanios S. Bekaii-Saab , Shubham Pant , Richard Hubner , Zhimin Xiao , Jia Li , Fawzi Benzaghou , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04083235
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 687)
DOI
10.1200/JCO.2024.42.3_suppl.687
Abstract #
687
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
First Author: Haeseong Park
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized multicenter phase II/III study of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX or S-IROX in patients with metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE).
First Author: Akihiro Ohba
Poster
2017 Gastrointestinal Cancers Symposium
Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma after failure of nab-paclitaxel plus gemcitabine.
First Author: Masato Ozaka
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).
First Author: Andrew Dean